Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GAD-alum in newly diagnosed type 1 diabetes (DiViD)
NCT01129232Phase 2Terminated
- Sponsor
- Oslo University Hospital
- Start
- Jan 2011
- Primary completion
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes, Subcutaneous Immunotherapy, Sublingual Immunotherapy
- Countries
- 1
01
Overview
A Phase 2 trial of Diamyd in type 1 diabetes mellitus (T1D), sponsored by Oslo University Hospital. Started Jan 2011; status: terminated.
02
Drugs
Diamyd
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01129232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01129232.